Bendamustine
Head and Neck Squamous Cell Carcinoma (HNSCC)
Cyteir Therapeutics, Inc.Small moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Head and Neck Squamous Cell Carcinoma (HNSCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Akeso | Phase 2 | BB |
Relatlimab Exelixis | Phase 2 | B |
Ulevostinag Merck Sharp & Dohme LLC | Phase 2 | B |
mt-4561 Tanabe Pharma America, Inc. | Phase 1/2 | CC |
ak129 Akeso | Phase 1/2 | CC |
View all 20 →
Same molecule, other indications
Bendamustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →